Evercore Has Lowered Expectations for Abbott Laboratories (NYSE:ABT) Stock Price
by Renee Jackson · The Cerbat GemAbbott Laboratories (NYSE:ABT – Get Free Report) had its target price decreased by Evercore from $138.00 to $134.00 in a research note issued on Monday,MarketScreener reports. The brokerage presently has an “outperform” rating on the healthcare product maker’s stock. Evercore’s price objective points to a potential upside of 30.99% from the stock’s current price.
ABT has been the topic of several other research reports. Weiss Ratings cut Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 26th. Royal Bank Of Canada reduced their price target on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Daiwa Securities Group lowered their price objective on shares of Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a research report on Friday, January 30th. Piper Sandler reduced their target price on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research report on Friday, January 23rd. Finally, Oppenheimer lowered their price target on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $135.47.
Check Out Our Latest Analysis on Abbott Laboratories
Abbott Laboratories Trading Down 0.6%
Shares of Abbott Laboratories stock opened at $102.30 on Monday. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $178.16 billion, a P/E ratio of 27.50, a price-to-earnings-growth ratio of 1.64 and a beta of 0.79. Abbott Laboratories has a 12-month low of $100.88 and a 12-month high of $139.06. The company has a 50-day simple moving average of $109.35 and a 200 day simple moving average of $120.71.
Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting the consensus estimate of $1.50. The company had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The company’s revenue was up 4.4% on a year-over-year basis. During the same quarter last year, the business posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Research analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.
Insider Buying and Selling at Abbott Laboratories
In other news, EVP Mary K. Moreland sold 613 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $70,850.54. Following the completion of the transaction, the executive vice president directly owned 104,291 shares in the company, valued at approximately $12,053,953.78. The trade was a 0.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Eric Shroff sold 709 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $81,946.22. Following the completion of the sale, the senior vice president owned 39,164 shares in the company, valued at approximately $4,526,575.12. This trade represents a 1.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 3,055 shares of company stock valued at $353,097 over the last quarter. 0.46% of the stock is owned by corporate insiders.
Institutional Trading of Abbott Laboratories
Hedge funds and other institutional investors have recently modified their holdings of the company. Charles Schwab Trust Co increased its holdings in Abbott Laboratories by 109.8% during the third quarter. Charles Schwab Trust Co now owns 29,412 shares of the healthcare product maker’s stock worth $3,939,000 after buying an additional 15,394 shares during the last quarter. Danica Pension Livsforsikringsaktieselskab bought a new position in Abbott Laboratories during the third quarter worth about $185,640,000. Asset Management One Co. Ltd. raised its stake in Abbott Laboratories by 2.4% in the third quarter. Asset Management One Co. Ltd. now owns 858,834 shares of the healthcare product maker’s stock valued at $115,032,000 after buying an additional 19,966 shares during the period. AE Wealth Management LLC increased its holdings in shares of Abbott Laboratories by 20.8% during the 3rd quarter. AE Wealth Management LLC now owns 65,504 shares of the healthcare product maker’s stock worth $8,774,000 after acquiring an additional 11,264 shares during the last quarter. Finally, Nordea Investment Management AB raised its stake in Abbott Laboratories by 6.1% in the 3rd quarter. Nordea Investment Management AB now owns 329,430 shares of the healthcare product maker’s stock valued at $43,785,000 after acquiring an additional 18,974 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.
About Abbott Laboratories
Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.
In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.